ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 950

Low-Dose IL-2 Effectively Restored Decreased Regulatory T Cells in Patients with Behcet’s Disease

Xiao-qing Liu1, Xiaojie Liu 2, Nalin Lai 3, Ting Cheng 1, Chong Gao 4 and Xiao-feng Li 1, 1The Second Hospital of Shanxi Medical University, Taiyuan, China (People's Republic), 2Taiyuan University of Technology, Taiyuan, China (People's Republic), 3Shanxi Medical University, Taiyuan, China (People's Republic), 4Brigham and Women’s Hospital, Harvard Medical School, Boston

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: interleukins (IL), T-Regulatory Cells and Behcet's syndrome

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: 3S112: Vasculitis – Non-ANCA-Associated & Related Disorders I: Miscellaneous Disorders (945–950)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Behcet’s disease (BD) is a chronic multisystemic disease characterized by muco-cutaneous and ocular manifestations, with central nervous system, vascular and/or gastro-intestinal involvement. Several studies have shown that immune mechanisms play an important role in the development of the disease and limited options of therapeutic medicines for BD. Low dose IL-2 has been reported to selectively promote the expansion of Treg. This study aimed to investigate the significance of Treg cells in the pathogenesis and the effect of low dose IL-2 on BD.

Methods: Absolute number of CD4+CD25+FOXP3+Treg, CD4+IL17+T (Th17) and other subsets in peripheral blood (PB) from 173 patients with BD and 90 healthy donors were characterized by flow cytometry combined with an internal microsphere counting standard. Thirty-nine patients were treated with daily subcutaneous injections of 0.5 million IU of human IL-2 for five consecutive days, and then its effects on lymphocyte subpopulations in PB were analyzed.

Results: There was a significant disturbance in lymphocyte subpopulations mainly manifested as the decreased level of Tregs compared with the health controls (median:22.32 cells/ul VS median:33.12 cells/ul, P< 0.001) and it was correlated negatively with BDCAF, ESR and CRP (P < 0.01), suggesting an important role of Tregs in sustained high disease activity. While no major difference in the absolute counts of circulating Th17 cells between patients with BD and health control. Accordingly, the ratios of Th17/Treg in patients with BD (median:0.38) were significantly higher than those of health control (median:0.21). Moreover, low dose IL-2 effectively increased the number of Tregs (P < 0.001) and re-balance the ratio of Th17 and Tregs, leading to clinic symptom partly remission in a rapid way without observed side effects.There was a significant disturbance in lymphocyte subpopulations mainly manifested as the decreased level of Tregs compared with the health controls (median:22.32 cells/ul VS median:33.12 cells/ul, P< 0.001) and it was correlated negatively with BDCAF, ESR and CRP (P < 0.01), suggesting an important role of Tregs in sustained high disease activity. While no major difference in the absolute counts of circulating Th17 cells between patients with BD and health control. Accordingly, the ratios of Th17/Treg in patients with BD (median:0.38) were significantly higher than those of health control (median:0.21). Moreover, low dose IL-2 effectively increased the number of Tregs (P < 0.001) and re-balance the ratio of Th17 and Tregs, leading to clinic symptom partly remission in a rapid way without observed side effects.

Conclusion: Absolute decrease of PB Tregs in patients with BD was associated with disease activity ,which might be the major reason for imbalance of Th17/Tregs. It is speculated that BD is an autoimmune disease triggered by the defect of immunotolerance. More importantly, low-dose IL-2 proposes a selective biological treatment strategy by restoring immune tolerance and promoting rapidly remission.


Disclosure: X. Liu, None; X. Liu, None; N. Lai, None; T. Cheng, None; C. Gao, None; X. Li, None.

To cite this abstract in AMA style:

Liu X, Liu X, Lai N, Cheng T, Gao C, Li X. Low-Dose IL-2 Effectively Restored Decreased Regulatory T Cells in Patients with Behcet’s Disease [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/low-dose-il-2-effectively-restored-decreased-regulatory-t-cells-in-patients-with-behcets-disease/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/low-dose-il-2-effectively-restored-decreased-regulatory-t-cells-in-patients-with-behcets-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology